Compare · NTLA vs TKNO
NTLA vs TKNO
Side-by-side comparison of Intellia Therapeutics Inc. (NTLA) and Alpha Teknova Inc. (TKNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NTLA and TKNO operate in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), so they compete in similar markets.
- NTLA is the larger of the two at $1.50B, about 5.6x TKNO ($266.5M).
- Over the past year, NTLA is down 21.1% and TKNO is down 4.1% - TKNO leads by 17.0 points.
- NTLA has been more active in the news (5 items in the past 4 weeks vs 2 for TKNO).
- NTLA has more recent analyst coverage (25 ratings vs 7 for TKNO).
- Company
- Intellia Therapeutics Inc.
- Alpha Teknova Inc.
- Price
- $10.73-3.33%
- $4.97-4.24%
- Market cap
- $1.50B
- $266.5M
- 1M return
- -30.82%
- -4.33%
- 1Y return
- -21.10%
- -4.15%
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- 2021
- News (4w)
- 5
- 2
- Recent ratings
- 25
- 7
Intellia Therapeutics Inc.
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. It utilizes a biological tool known as the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and Ospedale San Raffaele. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Latest NTLA
- EVP, Chief Financial Officer Dulac Edward J Iii sold $91,249 worth of shares (8,111 units at $11.25), decreasing direct ownership by 5% to 148,175 units (SEC Form 4) to satisfy withholding tax
- Intellia Therapeutics downgraded by Wolfe Research with a new price target
- VP, Chief Accounting Officer Dube Michael P sold $44,316 worth of shares (2,641 units at $16.78), decreasing direct ownership by 4% to 66,886 units (SEC Form 4) (tax liability)
- EVP, Chief Financial Officer Dulac Edward J Iii sold $84,186 worth of shares (4,677 units at $18.00) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 156,286 units (SEC Form 4)
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Intellia Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
- Director Verwiel Frank was granted 9,200 shares, increasing direct ownership by 35% to 35,148 units (SEC Form 4)
- Director Keresty Georgia was granted 9,200 shares, increasing direct ownership by 29% to 41,083 units (SEC Form 4)
- Director Goodman Jesse was granted 9,200 shares, increasing direct ownership by 38% to 33,559 units (SEC Form 4)
Latest TKNO
- Teknova to Report Second Quarter 2026 Financial Results on August 5, 2026
- Director Demski Martha J disposed of 12,000 shares and acquired 12,000 shares, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Vos Alexander
- SEC Form 4 filed by Director Robertson Brett
- SEC Form 4 filed by Director Demski Martha J
- Alpha Teknova Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- SEC Form 10-Q filed by Alpha Teknova Inc.
- Alpha Teknova Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits, Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
- Teknova Reports First Quarter 2026 Financial Results
- Teknova to Report First Quarter 2026 Financial Results on May 6, 2026